|
1. Biologie
|
|
|
CRISPR Dips into Cancer’s Pockets of Vulnerability [GEN]
|
|
|
|
|
|
This
article described how the scientists surveyed about 200 potential
targets in leukemia cells and successfully identified six targets
already known and validated by pharmaceutical scientists. The scientists
also found an additional 19 targets never before recognized.
|
|
|
|
|
|
|
|
|
|
2. Etiologie
|
|
|
Hormone oestrogen linked to male breast cancer [NHS Choices]
|
|
|
|
|
|
The
study used a good design and approach, and the findings seem plausible,
given what is known in women. However, it is still difficult to say
whether a raised oestrogen level is directly raising the risk of breast
cancer, or if both could be the result of another underlying factor.
|
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
|
GSK's Curious Oncology Research Position -- A Recipe For Failure? [Forbes]
|
|
|
|
|
|
From
an immediate financial point of view, it appears that GSK got a
reasonable deal for its Oncology business, fetching $16 billion for a
unit that brought in $1.7 billion in sales in 2013 largely from Tykerb,
Votrient, Promacta and Arzerra. However, this is an odd move given that
Oncology may be the hottest area of biopharmaceutical R&D today.
|
|
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.5 ASCO
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.9 Controverses
|
|
|